Report Overview

Global Remdesivir Market Forecast and Trends

The global market for Remdesivir is expected to expand at an impressive pace during the forecast period due, among others, to the growing use of the drug in the treatment of various diseases such as COVID-19, Ebola, SARS-COV, MERS-COV. The use of the COVID-19 drug, which once failed to treat Ebola, has now been granted an orphan drug status and clinical trials have begun to determine its efficacy in the treatment of novel coronavirus disease.

According to Gilead, the outcomes of the global, placebo-controlled trial conducted by the National Institute for Allergy and Infectious Diseases (NIAID) are promising, showing that patients with Covid-19 receiving Remdesivir recovered faster than comparable patients receiving placebo. Gilead Sciences, Inc. is currently conducting phase 3 clinical trials in Asia-Pacific, Europe and the US. Gilead published preliminary findings from its clinical trial on its antiviral drug Remdesivir, showing progress in at least 50% of COVID-19 patients treated with a 5-day dose of the drug. A research was then published by the National Institute of Allergy and Infectious Diseases that showed Covid-19 patients who took Remdesivir typically recovered after 11 days, four days faster than those who did not take the medication.

Global Remdesivir Market: Overview

Remdesivir is a nucleotide analog particularly to adenosine which shuts down the process of viral replication by inhibiting the activity of an important viral enzyme RNA-dependent polymerase RNA. The drug ultimately induces mutation in the viral genome and inhibits the functioning of polymerase enzymes, which leads to premature termination of viral replication.

Growth Drivers

The global demand for Remdesivir is driven by the growing prevalence of COVID-19 disease across all parts of the globe. It has not been clinically proven, though, but the studies suggest that Remdesivir has been effective in treating new patients with coronavirus disease across the globe. A research performed by Gilead Sciences Inc. on 53 prospective COVID-19 patients showed signs of progress in 36 patients, about 68% of the total number of patients. The Chinese used the medication mostly for compassionate use. WHO has guided the start of clinical trials for Remdesivir along with three other drugs found to be effective in COVID-19 therapy. The drug has now reached phase 3 of clinical trials and the world hopes it will emerge as a promising treatment for coronavirus. Following these positive trials, the Food and Drug Administration issued permission for the medication to treat Covid-19 for emergency use authorization (EUA). That means the medication has not undergone the same examination as therapies approved by the FDA, but it will allow doctors to prescribe Remdesivir to patients hospitalized with the disease. All supply of drugs will go to government for allocation across the nation.

Restraint

Remdesivir is still in clinical trials and was not FDA approved properly (approved in EUA category). This might hamper growth in the business. In fact, the medication once failed to cure Ebola, and there are many questions and misconceptions concerning its use on the market. Additionally, the cost of this medication is not known and people expect it would be very costly. This, too, could delay market growth by 2026. Countries have also begun to focus on the generic versions of medications, which may have a detrimental effect on consumer development.

Global Remdesivir Market: Route of Administration

The global market is bifurcated into oral and intravenous depending on the route of administration. Amidst the segmentation the intravenous route of administration is expected to dominate the market since the treatment of COVID-19 has been given to all patients solely through this route.

Global Remdesivir Market: Application

The market is segregated into Ebola, SARS-COV, MERS-COV, and COVID-19 based upon application. The product COVID-19 is expected to dominate the market for its successful use in the treatment of this disease. The drug has also entered clinical trials in phase 3, and is expected to emerge as a promising treatment choice for the pandemic. The drug also showed promising results for the SARS-COV and MERS-COV animal models

Global Remdesivir Market: Regional Insights

Due to the presence of the major players operating on the market, North America is projected to dominate the global Remdesivir market during the forecast period. In addition, the drug manufacturer Gilead Sciences is also headquartered in California, United States. At the other hand, the Asia-Pacific market is also projected to see substantial growth due to the widespread use of the medication for COVID-19 treatment in countries such as China, Japan, among others. Europe is projected to witness substantial growth in the overall demand for Remdesivir throughout the forecast period due to EMA's recommendation for the use of Remdesivir in compassionate COVID-19 care.

Competitive Landscape

Gilead Sciences, Inc., Bright Gene, Hainan Haiyao, Cipla, Pfizer, Merck, Cayman Chemical, Kelun Pharma, Hunan Warrant Pharmaceutical, Dr. Reddy's Laboratories and others are some of the major market leaders in Remdesivir. Organic strategies such as product launches, mergers and collaborations are used by the companies operating on the market to boost their share. Gilead Sciences, Inc., for instance, has announced it will donate 1.5 million doses of the medication for compassionate use. The company has also started manufacturing liquid and freeze-dried ways to improve supplies.

Recent Development

Ø  May, 2020: India has obtained 1,000 doses of Remdesivir, approved by the U.S. Food and Drug Administration for Covid-19 treatment, as part of the WHO's global solidarity trials, but pharmaceutical companies in India will have to wait for the patent route chosen by U.S. drug maker Gilead to start development here despite Indian scientists synthesizing Key Starting Materials (KSMs) from Remdesivir.

Ø  May 2020: The World Health Organization is planning to involve United States government and Gilead Sciences about how to make antiviral medication Remdesivir more widely accessible for treating Covid-19 as evidence emerges on its efficacy. Gilead expects to produce more than 140,000 rounds of its 10-day treatment scheme by the end of May, and anticipates that by the end of this year it will deliver 1 million rounds. Gilead said next year it would be able to manufacture "several million" rounds of their antiviral medication.

By Dosage

Ø  5mg

Ø  10mg

Ø  50mg

Ø  100mg

By Dosage Form

Ø  Tablets

Ø  Frozen Solution

Ø  Lyophilized Solution

By Route of Administration

Ø  Oral

Ø  Intravenous

By Application

Ø  Ebola

Ø  SARS-COV

Ø  MERS-COV

Ø  COVID-19

By Region:  

Ø  North America

Ø  Europe

Ø  Asia Pacific

Ø  Latin America

Ø  Middle East & Africa

The objective of the Study:

Ø  To analyze and forecast the global Remdesivir Market size of the market in terms of value.

Ø  To examine the careful market segmentation and forecast the market size, in terms of value, based on the region by segmenting.

Ø  The Global Remdesivir Market segmented into five regions, namely, North America, Europe, Asia Pacific, Latin America, Middle East & Africa and their leading countries.

Ø  To outline, categorized, and forecast the global Remdesivir Market is based on the dosage, dosage form, route of administration, distribution channel and application.

Ø  To examine competitive developments like technological advancement and regulative framework within the global Remdesivir Market.

Ø  To highlight the impact analysis of the factors affecting the market dynamics such as drivers, restraints, opportunities, and challenges.

Ø  To strategically profile the key players and comprehensively analyze their market shares along with detailing the competitive landscape for market leaders.